Paul Lilburn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Paul Lilburn has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Alvin J. Ing
Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia
3 shared publications Alvin Ing
Faculty of Medicine, Health and Human Sciences Macquarie University Sydney New South Wales Australia
2 shared publications- Jonathan Philip Williamson
Department of Respiratory and Sleep Medicine Liverpool Hospital Sydney Australia
2 shared publications Marshall Plit
Department of Medicine The Alfred, 55 Commercial Road Melbourne Victoria Australia
2 shared publicationsTajalli Saghaie
Faculty of Medicine, Health and Human Sciences Macquarie University Sydney New South Wales Australia
2 shared publications- Ai Ling Tan
Pleural Medicine Unit, Institute for Respiratory Health, Nedlands, Perth, WA 6009, Australia
1 shared publication
Latest Publications
- Open Access
- 20 October 2026
- Published by Taylor & Francis in Toxicology Communications
- Vol. 10 (1)
Delayed pulmonary abscess following hydrocarbon aspiration in a fire breather: a case report
- 20 October 2026
- Published by Taylor & Francis in Toxicology Communications
- Vol. 10 (1)
Open AccessDelayed pulmonary abscess following hydrocarbon aspiration in a fire breather: a case report
- Open Access
- 2 September 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (9)
Study Protocol of the Endobronchial VAlves for Pneumothorax to Reduce Admission Time ( EVAPoRATe ) Pilot Multicentre Randomised Clinical Trial
Background: Pneumothorax with persistent air leak (PAL) is a debilitating condition. Patients with PAL often require prolonged chest drainage, with associated complications, such as, hospital‐acquired infections, thromboembolism, and deconditioning. Endobronchial valves (EBVs) are an approved bronchoscopic treatment for PAL and may allow earlier chest tube removal and hospital discharge. Current evidence supporting the use of EBV is limited to case series and uncontrolled studies. EBVs are usually used as a last resort when other treatments failed. Whether early referral for EBV placement is feasible and can reduce hospital length of stay in patients with pneumothorax and PAL has not been tested in a randomised controlled trial (RCT). Methods: EVAPoRATe is a prospective, open‐labelled, pilot, multi‐centre RCT. Forty patients with pneumothorax of any cause and PAL who are unsuitable for or unwilling to undergo surgical management will be randomised 1:1 to the Early EBV Referral arm or the Standard Care arm. Patients in the Early EBV Referral arm will be assessed by an interventional clinician for EBV placement at the earliest feasible time from Day 5 of pneumothorax. Patients allocated to the Standard Care arm will receive conventional management by the attending team; EBV is allowed if clinically appropriate when air leak persists after 12 days. Participants will be followed for 6 months after discharge. Discussion: The primary outcome is the feasibility of the trial protocol, assessed by recruitment rate, adherence to the intervention arm, and retention at follow‐up. Secondary outcomes include total hospital length of stay, PAL‐related length of stay, interventions for PAL and EBV complications, time to air leak cessation, time to chest drain removal, pneumothorax recurrence, adverse events and serious adverse events, removal of EBVs, performance status, and mortality. This pilot feasibility study will assess whether a future full‐scale RCT of EBV for PAL is practical and will provide data to guide protocol refinement and sample size calculation. Trial Registration: Australian New Zealand Clinical Trials Registry: ACTRN12625000360415; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=388086&isReview=true
- 2 September 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (9)
Open AccessStudy Protocol of the Endobronchial VAlves for Pneumothorax to Reduce Admission Time ( EVAPoRATe ) Pilot Multicentre Randomised Clinical Trial
Background: Pneumothorax with persistent air leak (PAL) is a debilitating condition. Patients with PAL often require prolonged chest drainage, with associated complications, such as, hospital‐acquired infections, thromboembolism, and deconditioning. Endobronchial valves (EBVs) are an approved bronchoscopic treatment for PAL and may allow earlier chest tube removal and hospital discharge. Current evidence supporting the use of EBV is limited to case series and uncontrolled studies. EBVs are usually used as a last resort when other treatments failed. Whether early referral for EBV placement is feasible and can reduce hospital length of stay in patients with pneumothorax and PAL has not been tested in a randomised controlled trial (RCT). Methods: EVAPoRATe is a prospective, open‐labelled, pilot, multi‐centre RCT. Forty patients with pneumothorax of any cause and PAL who are unsuitable for or unwilling to undergo surgical management will be randomised 1:1 to the Early EBV Referral arm or the Standard Care arm. Patients in the Early EBV Referral arm will be assessed by an interventional clinician for EBV placement at the earliest feasible time from Day 5 of pneumothorax. Patients allocated to the Standard Care arm will receive conventional management by the attending team; EBV is allowed if clinically appropriate when air leak persists after 12 days. Participants will be followed for 6 months after discharge. Discussion: The primary outcome is the feasibility of the trial protocol, assessed by recruitment rate, adherence to the intervention arm, and retention at follow‐up. Secondary outcomes include total hospital length of stay, PAL‐related length of stay, interventions for PAL and EBV complications, time to air leak cessation, time to chest drain removal, pneumothorax recurrence, adverse events and serious adverse events, removal of EBVs, performance status, and mortality. This pilot feasibility study will assess whether a future full‐scale RCT of EBV for PAL is practical and will provide data to guide protocol refinement and sample size calculation. Trial Registration: Australian New Zealand Clinical Trials Registry: ACTRN12625000360415; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=388086&isReview=true
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Medicine
- Vol. 2025 (1)
Beating the Odds: A Successful Pregnancy in a Patient With ALK‐Rearranged Lung Cancer on Alectinib
The management of oncogene‐driven non–small cell lung cancer (NSCLC) during pregnancy presents unique challenges due to limited safety data on targeted therapies. Anaplastic lymphoma kinase (ALK)‐rearranged NSCLC is a rare but increasingly recognized entity in young women, including during pregnancy. Here, we report the case of a 37‐year‐old woman diagnosed with metastatic ALK‐rearranged NSCLC during her first pregnancy, who was commenced on alectinib. Following this, she had a successful second pregnancy whilst being treated with alectinib (withheld during weeks 6–10 of gestation to avoid the critical period of organogenesis). Both pregnancies resulted in healthy infants with no complications or evidence of developmental delays. This case highlights the importance of a multidisciplinary approach involving oncology, maternal‐fetal medicine, clinical genetics, obstetrics medicine, and obstetrics to balance maternal cancer control and fetal health. While preclinical studies of alectinib suggest teratogenic risks, this and other reported cases demonstrate its potential for safe use during pregnancy with careful planning. Pathological examination of the placenta in our case revealed no malignant cells, and maternal disease remained controlled. As targeted therapies extend survival in advanced NSCLC, more patients may contemplate pregnancy, emphasizing the need for robust evidence to guide treatment decisions. This case contributes to the growing body of evidence supporting the feasibility of managing pregnancy in patients with ALK‐rearranged NSCLC using targeted therapies like alectinib, while underscoring the importance of long‐term follow‐up for the exposed offspring.
- 1 January 2025
- Published by Wiley in Case Reports in Medicine
- Vol. 2025 (1)
Open AccessBeating the Odds: A Successful Pregnancy in a Patient With ALK‐Rearranged Lung Cancer on Alectinib
The management of oncogene‐driven non–small cell lung cancer (NSCLC) during pregnancy presents unique challenges due to limited safety data on targeted therapies. Anaplastic lymphoma kinase (ALK)‐rearranged NSCLC is a rare but increasingly recognized entity in young women, including during pregnancy. Here, we report the case of a 37‐year‐old woman diagnosed with metastatic ALK‐rearranged NSCLC during her first pregnancy, who was commenced on alectinib. Following this, she had a successful second pregnancy whilst being treated with alectinib (withheld during weeks 6–10 of gestation to avoid the critical period of organogenesis). Both pregnancies resulted in healthy infants with no complications or evidence of developmental delays. This case highlights the importance of a multidisciplinary approach involving oncology, maternal‐fetal medicine, clinical genetics, obstetrics medicine, and obstetrics to balance maternal cancer control and fetal health. While preclinical studies of alectinib suggest teratogenic risks, this and other reported cases demonstrate its potential for safe use during pregnancy with careful planning. Pathological examination of the placenta in our case revealed no malignant cells, and maternal disease remained controlled. As targeted therapies extend survival in advanced NSCLC, more patients may contemplate pregnancy, emphasizing the need for robust evidence to guide treatment decisions. This case contributes to the growing body of evidence supporting the feasibility of managing pregnancy in patients with ALK‐rearranged NSCLC using targeted therapies like alectinib, while underscoring the importance of long‐term follow‐up for the exposed offspring.
- 15 May 2024
- Published by Wiley in Internal Medicine Journal
- Vol. 54 (6) , 849-851
Endoscopic lung volume reduction with endobronchial valves for severe chronic obstructive pulmonary disease: a coming of age in Australia
- 15 May 2024
- Published by Wiley in Internal Medicine Journal
- Vol. 54 (6) , 849-851
Endoscopic lung volume reduction with endobronchial valves for severe chronic obstructive pulmonary disease: a coming of age in Australia
- Open Access
- 22 December 2023
- Published by Wiley in Internal Medicine Journal
- Vol. 54 (2) , 204-213
Tracheobronchial stents: an expanding prospect
The first dedicated tracheobronchial silicone stent was designed by the French pulmonologist Jean‐Paul Dumon. The most common indications for stenting are to minimise extrinsic airway compression from mass effect, maintain airway patency due to intrinsic obstruction or treat significant nonmalignant airway narrowing or fistulae. Silicone stents require rigid bronchoscopy for insertion; however, they are more readily repositioned and removed compared with metallic stents. Metallic stents demonstrate luminal narrowing when loads are applied to their ends, therefore stents should either be reinforced at the ends or exceed the area of stenosis by a minimum of 5 mm. Nitinol, a nickel‐titanium metal alloy, is currently the preferred material used for airway stents. Airway stenting provides effective palliation for patients with severe symptomatic obstruction. Drug‐eluting and three‐dimensional printing of airway stents present promising solutions to the challenges of the physical and anatomical constraints of the tracheobronchial tree. Biodegradable stents could also be a solution for the treatment of nonmalignant airway obstruction.
- 22 December 2023
- Published by Wiley in Internal Medicine Journal
- Vol. 54 (2) , 204-213
Open AccessTracheobronchial stents: an expanding prospect
The first dedicated tracheobronchial silicone stent was designed by the French pulmonologist Jean‐Paul Dumon. The most common indications for stenting are to minimise extrinsic airway compression from mass effect, maintain airway patency due to intrinsic obstruction or treat significant nonmalignant airway narrowing or fistulae. Silicone stents require rigid bronchoscopy for insertion; however, they are more readily repositioned and removed compared with metallic stents. Metallic stents demonstrate luminal narrowing when loads are applied to their ends, therefore stents should either be reinforced at the ends or exceed the area of stenosis by a minimum of 5 mm. Nitinol, a nickel‐titanium metal alloy, is currently the preferred material used for airway stents. Airway stenting provides effective palliation for patients with severe symptomatic obstruction. Drug‐eluting and three‐dimensional printing of airway stents present promising solutions to the challenges of the physical and anatomical constraints of the tracheobronchial tree. Biodegradable stents could also be a solution for the treatment of nonmalignant airway obstruction.
- Open Access
- 7 August 2023
- Published by Wiley in Respirology
- Vol. 28 (11) , 1053-1059
Safety and efficacy of bronchial thermoplasty in Australia 5 years post‐procedure
Background and Objective: Outside clinical trials, there is limited long‐term data following bronchial thermoplasty (BT). In a cohort of real‐world severe asthmatics in an era of biological therapy, we sought to evaluate the safety and efficacy of BT 5 years post‐treatment.Methods: Every patient treated with BT at two Australian tertiary centres were recalled at 5 years, and evaluated by interview and record review, Asthma Control Questionnaire (ACQ), spirometry and high‐resolution CT Chest. CT scans were interpreted using the modified Reiff and BRICS CT scoring systems for bronchiectasis.Results: Fifty‐one patients were evaluated. At baseline, this cohort had a mean age of 59.0 ± 11.8 years, mean ACQ of 3.0 ± 1.0, mean FEV1 of 55.5 ± 18.8% predicted, and 53% were receiving maintenance oral steroids in addition to triple inhaler therapy. At 5 years, there was a sustained improvement in ACQ scores to 1.8 ± 1.0 (p < 0.001). Steroid requiring exacerbation frequency was reduced from 3.8 ± 3.6 to 1.0 ± 1.6 exacerbations per annum (p < 0.001). 44% of patients had been weaned off oral steroids. No change in spirometry was observed.CT scanning identified minor degrees of localized radiological bronchiectasis in 23/47 patients with the modified Reiff score increasing from 0.6 ± 2.6 at baseline to 1.3 ± 2.5 (p < 0.001). However, no patients exhibited clinical features of bronchiectasis, such as recurrent bacterial infection.Conclusion: Sustained clinical benefit from BT at 5 years was demonstrated in this cohort of very severe asthmatics. Mild, localized radiological bronchiectasis was identified in a portion of patients without clinical features of bronchiectasis.
- 7 August 2023
- Published by Wiley in Respirology
- Vol. 28 (11) , 1053-1059
Open AccessSafety and efficacy of bronchial thermoplasty in Australia 5 years post‐procedure
Background and Objective: Outside clinical trials, there is limited long‐term data following bronchial thermoplasty (BT). In a cohort of real‐world severe asthmatics in an era of biological therapy, we sought to evaluate the safety and efficacy of BT 5 years post‐treatment.Methods: Every patient treated with BT at two Australian tertiary centres were recalled at 5 years, and evaluated by interview and record review, Asthma Control Questionnaire (ACQ), spirometry and high‐resolution CT Chest. CT scans were interpreted using the modified Reiff and BRICS CT scoring systems for bronchiectasis.Results: Fifty‐one patients were evaluated. At baseline, this cohort had a mean age of 59.0 ± 11.8 years, mean ACQ of 3.0 ± 1.0, mean FEV1 of 55.5 ± 18.8% predicted, and 53% were receiving maintenance oral steroids in addition to triple inhaler therapy. At 5 years, there was a sustained improvement in ACQ scores to 1.8 ± 1.0 (p < 0.001). Steroid requiring exacerbation frequency was reduced from 3.8 ± 3.6 to 1.0 ± 1.6 exacerbations per annum (p < 0.001). 44% of patients had been weaned off oral steroids. No change in spirometry was observed.CT scanning identified minor degrees of localized radiological bronchiectasis in 23/47 patients with the modified Reiff score increasing from 0.6 ± 2.6 at baseline to 1.3 ± 2.5 (p < 0.001). However, no patients exhibited clinical features of bronchiectasis, such as recurrent bacterial infection.Conclusion: Sustained clinical benefit from BT at 5 years was demonstrated in this cohort of very severe asthmatics. Mild, localized radiological bronchiectasis was identified in a portion of patients without clinical features of bronchiectasis.
- Open Access
- 19 June 2023
- Published by Wiley in Respirology Case Reports
- Vol. 11 (7) , e01174
Endobronchial indocyanine green instillation to identify the intersegmental plane for successful segmentectomy
The traditional indications for lobectomy for resectable Non‐small Cell Lung Cancer (NSCLC) may be set to change. Recently, anatomical segmentectomy (AS) versus lobectomy as an approach for early‐stage NSCLC has been described in phase 3 randomised controlled trials. The demand for methods to facilitate AS may increase as a consequence. We describe three cases of AS using the combination of endobronchial infiltration of indocyanine green (ICG) to identify the intersegmental plane (critical for the performance of AS), and Computed Tomography (CT) guided methylene blue injection for lesion localisation. The operations were completed successfully demonstrating satisfactory post‐operative outcomes including lesion resection with clear surgical margins and acceptable length of stay. We believe that endobronchial instillation of ICG and CT‐guided methylene blue injection for lesion localisation show promise as a technique to complement parenchymal sparing thoracic oncological surgery.
- 19 June 2023
- Published by Wiley in Respirology Case Reports
- Vol. 11 (7) , e01174
Open AccessEndobronchial indocyanine green instillation to identify the intersegmental plane for successful segmentectomy
The traditional indications for lobectomy for resectable Non‐small Cell Lung Cancer (NSCLC) may be set to change. Recently, anatomical segmentectomy (AS) versus lobectomy as an approach for early‐stage NSCLC has been described in phase 3 randomised controlled trials. The demand for methods to facilitate AS may increase as a consequence. We describe three cases of AS using the combination of endobronchial infiltration of indocyanine green (ICG) to identify the intersegmental plane (critical for the performance of AS), and Computed Tomography (CT) guided methylene blue injection for lesion localisation. The operations were completed successfully demonstrating satisfactory post‐operative outcomes including lesion resection with clear surgical margins and acceptable length of stay. We believe that endobronchial instillation of ICG and CT‐guided methylene blue injection for lesion localisation show promise as a technique to complement parenchymal sparing thoracic oncological surgery.
- 30 May 2023
- Published by Wiley in Respirology
- Vol. 28 (8) , 804-806
Bronchiectasis is associated with coronary artery calcification even in never smokers
- 30 May 2023
- Published by Wiley in Respirology
- Vol. 28 (8) , 804-806
Bronchiectasis is associated with coronary artery calcification even in never smokers
- Open Access
- 23 May 2023
- Published by Wiley in Respirology Case Reports
- Vol. 11 (6)
A hole lot of trouble: Severe bilateral anastomotic dehiscence following bilateral single sequential lung transplant
Airway complications post lung transplant including ischaemia and dehiscence have a significant associated mortality (2%–4%) and morbidity. We describe a case of a 22‐year‐old female who developed significant bilateral anastomotic dehiscence with severe ischaemia following a bilateral single sequential lung transplant (BSSLTx). Following an intensive antimicrobial regimen, judicious bronchoscopic surveillance, and a prolonged inpatient stay, the dehiscence resolved without requiring further surgical intervention. Our case highlights a space in the literature for further research with regard to airway complications post‐lung transplant and their management.
- 23 May 2023
- Published by Wiley in Respirology Case Reports
- Vol. 11 (6)
Open AccessA hole lot of trouble: Severe bilateral anastomotic dehiscence following bilateral single sequential lung transplant
Airway complications post lung transplant including ischaemia and dehiscence have a significant associated mortality (2%–4%) and morbidity. We describe a case of a 22‐year‐old female who developed significant bilateral anastomotic dehiscence with severe ischaemia following a bilateral single sequential lung transplant (BSSLTx). Following an intensive antimicrobial regimen, judicious bronchoscopic surveillance, and a prolonged inpatient stay, the dehiscence resolved without requiring further surgical intervention. Our case highlights a space in the literature for further research with regard to airway complications post‐lung transplant and their management.
- Open Access
- 12 April 2023
- Published by Hindawi Limited in Case Reports in Transplantation
- Vol. 2023, 1-6
Inescapable Fibrosis: The Development of Desquamative Interstitial Pneumonia Post-Lung Transplantation Performed for a Patient with Idiopathic Pulmonary Fibrosis
Interstitial lung disease is characterised by a combination of cellular proliferation, inflammation of the interstitium and fibrosis within the alveolar wall. A 58-year-old man was referred for lung transplantation after developing worsening dyspnoea and progressive hypoxaemic respiratory failure from idiopathic pulmonary fibrosis. Three years later, he developed desquamative interstitial pneumonia in his transplanted lungs, and despite augmentation of immune suppression, he had a progressive decline in his lung function and exercise capacity. Interestingly, in our case, the histopathology obtained post transplant strongly goes against the recurrence of usual interstitial pneumonia/idiopathic pulmonary fibrosis; rather, two separate interstitial disease processes have been identified.
- 12 April 2023
- Published by Hindawi Limited in Case Reports in Transplantation
- Vol. 2023, 1-6
Open AccessInescapable Fibrosis: The Development of Desquamative Interstitial Pneumonia Post-Lung Transplantation Performed for a Patient with Idiopathic Pulmonary Fibrosis
Interstitial lung disease is characterised by a combination of cellular proliferation, inflammation of the interstitium and fibrosis within the alveolar wall. A 58-year-old man was referred for lung transplantation after developing worsening dyspnoea and progressive hypoxaemic respiratory failure from idiopathic pulmonary fibrosis. Three years later, he developed desquamative interstitial pneumonia in his transplanted lungs, and despite augmentation of immune suppression, he had a progressive decline in his lung function and exercise capacity. Interestingly, in our case, the histopathology obtained post transplant strongly goes against the recurrence of usual interstitial pneumonia/idiopathic pulmonary fibrosis; rather, two separate interstitial disease processes have been identified.